Accessibility Menu
Nexien BioPharma logo

Nexien BioPharma(OTC) NXEN

Market Cap$7.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-99%
1 Month+0%
$0.00
+0.00%
+0.00Today
Nexien BioPharma last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-23
Nexien BioPharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-06-11
1 month+0%USD 0.002026-06-11
3 month+0%USD 0.002026-04-10
Year to date+0%USD 0.002025-12-12
1 year-98.51%USD 0.012025-07-23
3 year-99.67%USD 0.032023-07-24
5 year-99.86%USD 0.072021-07-23
Since inception-99.99%USD 1.962017-10-16

Nexien BioPharma Financials at a Glance

Market Cap

$7.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$188.08K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-2.08 (Low)

Price

$0.00

Volume

63

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

May 12, 2026

NXEN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nexien BioPharma

Nexien BioPharma, Inc. is a pharmaceutical company based in Glendale, Colorado, focused on the research and development of cannabinoid-derived medications. The company aims to address various diseases and medical conditions through innovative therapeutic solutions.

Products and Services
  • Research and development of cannabinoid-based therapies
  • Clinical trials targeting various medical conditions
  • Pre-clinical development of novel drug formulations
Growth Outlook
  • Significant market potential in cannabinoid-derived medications
  • Increased interest in alternative therapies among healthcare providers
  • Expansion of clinical trials to validate product efficacy
Financial Highlights
  • Recent quarterly net income of -$30,092
  • Trailing twelve months (TTM) revenue remains at $0
  • Current assets of $8,285 with total liabilities of $458,801
Nexien BioPharma, Inc. operates in a rapidly evolving sector, with a focus on cannabinoid-based treatments that are gaining traction in the healthcare industry. The company's commitment to research and development positions it well to capitalize on the growing demand for alternative therapies. Despite recent financial challenges, including a net income loss, the potential for growth in this niche market remains significant. Investors may find interest in the company's innovative approach and the expanding landscape of cannabinoid-derived medications.
AI Generated • Jul 17, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Richard Greenberg

Website

www.nexienbiopharma.com

Headquarters

Glendale, CO 80246, US

NXEN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

77.94%

Return on Capital

N/A

Return on Assets

-5713.60%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

70.77M

Volume

63

Avg. Volume

334.613

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$118.32K

EBITDA

-$64.29K

Operating Cash Flow

-$61.78K

Capital Expenditure

$1.00

Free Cash Flow

-$61.78K

Cash & ST Invst.

$8.29K

Total Debt

$375.38K

Nexien BioPharma Performance Analysis

Nexien BioPharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30USD 0N/A
20232023-06-30USD 0N/A
20242024-06-30USD 0N/A
Nexien BioPharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30N/A
Q12024-09-30N/A
Q22024-12-31N/A
Q32025-03-31N/A
Nexien BioPharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30USD -0.01N/A
20232023-06-30USD -0.01-46.3%
20242024-06-30USD -0.00-37.9%
Nexien BioPharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-75.0%
Q12024-09-3064.3%
Q22024-12-31-20.0%
Q32025-03-3133.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$7.10KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$710.00

N/A

Employees

10

N/A

Net Income

-$30.09K

+43.4%

EBITDA

$0.00

N/A

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$8.29K

-17.7%

Total Debt

$375.38K

+27.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$375.38K

+27.2%

Return on Assets

-57.14%

N/A

Return on Invested Capital

43.18%

N/A

Free Cash Flow

-$13.02K

+37.9%

Operating Cash Flow

-$13.02K

+37.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RGMPRegnum Corp.
$0.00+0.00%
NEPTFNeptune Wellness Solutions Inc.
$0.00+0.00%
DVLPGolden Developing Solutions, Inc.
$0.00+0.00%
ACUSAcusphere, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About NXEN

What is the current price of Nexien BioPharma?

Nexien BioPharma is trading at $0.00 per share.

What is the 52-week range for Nexien BioPharma?

Over the past 52 weeks, Nexien BioPharma has traded between $0.00 and $0.01.

How much debt does Nexien BioPharma have?

As of the most recent reporting period, Nexien BioPharma reported total debt of $375.38K.

How much cash does Nexien BioPharma have on hand?

Nexien BioPharma reported $8.29K in cash and cash equivalents in its most recent financial results.

What is Nexien BioPharma’s dividend yield?

Nexien BioPharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services